Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Passes Below 200-Day Moving Average of $0.44

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBPGet Rating)’s stock price passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.44 and traded as low as $0.22. Corbus Pharmaceuticals shares last traded at $0.23, with a volume of 914,362 shares changing hands.

Separately, StockNews.com assumed coverage on shares of Corbus Pharmaceuticals in a report on Friday. They issued a “hold” rating on the stock.

The stock has a market capitalization of $29.18 million, a PE ratio of -0.71 and a beta of 2.04. The company has a debt-to-equity ratio of 0.22, a quick ratio of 5.85 and a current ratio of 5.85. The stock’s 50 day moving average is $0.32 and its two-hundred day moving average is $0.44.

Corbus Pharmaceuticals (NASDAQ:CRBPGet Rating) last announced its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Corbus Pharmaceuticals had a negative net margin of 2,856.56% and a negative return on equity of 54.78%. Equities research analysts expect that Corbus Pharmaceuticals Holdings, Inc. will post -0.24 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the business. Spire Wealth Management purchased a new position in Corbus Pharmaceuticals in the 4th quarter valued at approximately $28,000. JPMorgan Chase & Co. lifted its position in shares of Corbus Pharmaceuticals by 211.1% during the 4th quarter. JPMorgan Chase & Co. now owns 107,590 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 73,008 shares during the last quarter. Aries Wealth Management lifted its position in shares of Corbus Pharmaceuticals by 360.7% during the 4th quarter. Aries Wealth Management now owns 107,800 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 84,400 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in shares of Corbus Pharmaceuticals by 27.5% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 115,919 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new stake in Corbus Pharmaceuticals during the 3rd quarter worth $107,000. 35.61% of the stock is owned by institutional investors.

Corbus Pharmaceuticals Company Profile (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.